Barrington Research Reiterates Outperform Rating for Haemonetics (NYSE:HAE)

Haemonetics (NYSE:HAE - Get Free Report)'s stock had its "outperform" rating reaffirmed by analysts at Barrington Research in a report issued on Friday,Benzinga reports. They presently have a $95.00 price target on the medical instruments supplier's stock. Barrington Research's price target points to a potential upside of 24.04% from the company's previous close. Barrington Research also issued estimates for Haemonetics' Q1 2026 earnings at $1.02 EPS, Q1 2027 earnings at $1.13 EPS, Q2 2027 earnings at $1.33 EPS, Q3 2027 earnings at $1.49 EPS and Q4 2027 earnings at $1.45 EPS.

Several other research analysts also recently commented on the company. Needham & Company LLC cut their target price on Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Raymond James Financial reissued a "strong-buy" rating and issued a $105.00 price target (down from $115.00) on shares of Haemonetics in a report on Friday, May 9th. JMP Securities restated a "market outperform" rating and issued a $100.00 price objective on shares of Haemonetics in a research report on Tuesday, May 20th. Baird R W raised shares of Haemonetics to a "strong-buy" rating in a report on Wednesday, June 25th. Finally, Citigroup upgraded shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 target price on the stock in a research note on Wednesday, July 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $97.30.

Haemonetics Stock Performance

Shares of HAE traded up $1.07 during trading hours on Friday, hitting $76.59. The company's stock had a trading volume of 573,345 shares, compared to its average volume of 675,615. The business has a 50 day simple moving average of $70.73 and a two-hundred day simple moving average of $67.91. Haemonetics has a 52-week low of $55.30 and a 52-week high of $94.99. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.62 and a quick ratio of 0.99. The company has a market cap of $3.68 billion, a price-to-earnings ratio of 23.14, a PEG ratio of 1.22 and a beta of 0.39.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, topping the consensus estimate of $1.22 by $0.02. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. The company had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. During the same period last year, the firm earned $0.90 EPS. Haemonetics's revenue for the quarter was down 3.5% on a year-over-year basis. On average, equities analysts expect that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HAE. TD Waterhouse Canada Inc. purchased a new position in shares of Haemonetics during the fourth quarter worth approximately $25,000. GAMMA Investing LLC grew its holdings in shares of Haemonetics by 59.4% during the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier's stock valued at $33,000 after purchasing an additional 165 shares during the last quarter. Quarry LP grew its holdings in shares of Haemonetics by 63.4% during the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock valued at $31,000 after purchasing an additional 192 shares during the last quarter. UMB Bank n.a. raised its position in Haemonetics by 91.7% in the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier's stock worth $50,000 after purchasing an additional 320 shares during the period. Finally, Covestor Ltd lifted its stake in Haemonetics by 146.8% in the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after purchasing an additional 439 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.